Literature DB >> 19595912

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease.

David S Knopman1.   

Abstract

Entities:  

Year:  2007        PMID： 19595912     DOI： 10.1016/j.jalz.2006.10.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  3 in total

Review 1.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

2.  Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease.

Authors:  Oliver Peters; Manuel Fuentes; Lisa Katharina Joachim; Frank Jessen; Christian Luckhaus; Johannes Kornhuber; Johannes Pantel; Michael Hüll; Klaus Schmidtke; Eckart Rüther; Hans-Jürgen Möller; Alexander Kurz; Jens Wiltfang; Wolfgang Maier; Birgitt Wiese; Lutz Frölich; Isabella Heuser
Journal:  Alzheimers Dement (N Y)       Date:  2015-10-19

Review 3.  Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders.

Authors:  Francisco de Assis Carvalho do Vale; Ylmar Corrêa Neto; Paulo Henrique Ferreira Bertolucci; João Carlos Barbosa Machado; Delson José da Silva; Nasser Allam; Márcio Luiz Figueredo Balthazar
Journal:  Dement Neuropsychol       Date:  2011 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.